医学
英夫利昔单抗
潜伏性肺结核
免疫学
细胞因子
干扰素
肺结核
生物标志物
离体
肿瘤坏死因子α
干扰素γ
地塞米松
结核分枝杆菌
体内
内科学
病理
生物
生物技术
生物化学
作者
Alexander J. Edwards,Yifang Gao,R N Allan,Darran Ball,Hans de Graaf,Tracy Coelho,Vanessa Clifford,Nigel Curtis,Anthony P. Williams,Saul N. Faust,Salah Mansour,Ben G. Marshall,Paul Elkington,Marc Tebruegge
出处
期刊:Thorax
[BMJ]
日期:2017-02-03
卷期号:72 (10): 946-949
被引量:43
标识
DOI:10.1136/thoraxjnl-2016-209397
摘要
The impact of immunosuppression on interferon-γ release assays and novel cytokine biomarkers of TB infection, mycobacteria-specific IL-2, IP-10 and TNF-α responses was investigated in an ex vivo model. Cytokine responses in standard QuantiFERON-TB Gold in-Tube (QFT-GIT) assays were compared with duplicate assays containing dexamethasone or infliximab. Dexamethasone converted QFT-GIT results from positive to negative in 30% of participants. Antigen-stimulated interferon-γ, IL-2 and TNF-α responses were markedly reduced, but IP-10 responses were preserved. Infliximab caused QFT-GIT result conversion in up to 30% of participants and substantial reductions in all cytokine responses. Therefore, corticosteroids and anti-TNF-α agents significantly impair interferon-γ release assay performance. IP-10 may be a more robust TB biomarker than interferon-γ in patients receiving corticosteroids.
科研通智能强力驱动
Strongly Powered by AbleSci AI